# Accurate International Biotechnology (ACCURATE)

> Guangzhou, China biotechnology company (founded 2018) building the organoid technology
> industry chain for cancer precision medicine, new-drug R&D and regenerative medicine.
> ACCURATE sells laboratory reagents, chips, instruments and clinical testing services.
> It publishes NO public API, developer portal, SDK, CLI or machine-readable specification.

<!--
generated: 2026-09-06
method: generated
source: apis.yml + https://en.bio-accurate.com/ + https://en.bio-accurate.com/company/ (fetched 2026-09-06)
note: Generated by the API Evangelist enrichment pipeline. ACCURATE does not serve its own
      /llms.txt — https://en.bio-accurate.com/llms.txt returns HTTP 200 with the site's
      ThinkPHP soft-404 error page, not a document.
-->

## What it is

- Legal/trading names: Accurate International Biotechnology; ACCURATE
- Headquarters: 6th Floor, Building C3, Enterprise Accelerator, No. 11 Kaiyuan Avenue,
  Huangpu District, Guangzhou, China
- Founded: 2018
- Subsidiaries: Accurate Biotechnology (Beijing); Accurate Biotechnology (Shanghai);
  Macau Ahavagen Biotechnology; Guangzhou Chuangxin Independent Clinical Laboratory;
  SUPERBIA SOCIETA BENEFIT SRL (Europe)
- Funding: Pre-A (2020), Series A (2021), Pre-B 100M RMB (2022), Series B (2024)
- Reported scale: 32,000+ organoid cultures, 5,000+ tumor organoid models,
  200+ clinical collaborators, 100+ filed patents

## Products (physical, not software)

- Accuroid organoid culture media
- AccuArray microarray organoid chip
- AOMF microfluidic organoid chip and AOMF organoid 3D bioprinter
- AccuLumi high-throughput chemiluminescence detector
- Accuauto automated organoid culture workstations

## Services

- BUDcare / BUDhealth patient-derived tumor organoid drug-sensitivity testing
- Organoid-model new-drug R&D services for pharmaceutical partners
- Clinical decision support for oncologists (delivered through its own clinical laboratory)

## Internal digital assets (no public interface)

- AOD Tronchip organoid big database (launched 2023)
- Cancer "deep-thinking" AI large model built on organoid + clinical data (2024)

Neither is exposed as a public API, dataset download, or documented query interface.

## Links

- Website (English): https://en.bio-accurate.com/
- Website (Chinese): https://www.bio-accurate.com/
- About: https://en.bio-accurate.com/company/
- Technology platform: https://en.bio-accurate.com/jishupintai/
- New drug R&D service: https://en.bio-accurate.com/newmedicine/
- Clinical service: https://en.bio-accurate.com/linchuang/
- News: https://en.bio-accurate.com/news/dynamic/

## API surface — measured, 2026-09-06

- No OpenAPI/Swagger: /openapi.json, /openapi.yaml, /swagger.json, /api-docs and /docs on
  en.bio-accurate.com and www.bio-accurate.com either time out or return the site's
  200-status ThinkPHP soft-404 HTML shell. No document parses as OpenAPI.
- No GraphQL, gRPC/protobuf, WSDL, AsyncAPI or webhook surface published.
- No MCP server and no A2A agent card: /.well-known/agent-card.json and
  /.well-known/agent.json return 404 on both hosts.
- No /.well-known/ documents at all: security.txt, openid-configuration,
  oauth-authorization-server, api-catalog, ai-plugin.json and aauth-resource.json all 404.
- No API-shaped subdomains: api., db., data., cloud., open., developer., dev., platform. and
  organoid..bio-accurate.com are all NXDOMAIN.
- The only HTTP endpoints the site itself calls are CSRF-protected first-party form handlers
  (/sendSms/, the contact-form POST) — site plumbing, not a public API.
- Domain security (probed): TLSv1.3 with HSTS max-age 31536000 on en.bio-accurate.com;
  no DNSSEC, no CAA, no SPF, no DMARC on bio-accurate.com.